Restricted accessResearch articleFirst published online 2025-10
Exploring the stability of Alzheimer's disease plasma biomarkers stored for extended periods at −20°C: Implications for resource-constrained environments
Plasma samples for Alzheimer's disease biomarker analysis are ideally stored at −80°C, which is challenging in low research resource settings. We assessed the stability of pTau181, Aβ42, Aβ40, NfL, and GFAP in plasma stored at −20°C for 2, 4, 6, and 15 weeks using single molecule array assays. No significant variation was observed in pTau181 and Aβ42/Aβ40 ratio across all timepoints. NfL and GFAP showed greater variability. These findings indicate the stability of these Alzheimer's disease related analytes for up to 15 weeks at −20°C though future studies of other biomarkers and timeframes are recommended.
World Health Organization. Global action plan on the public health response to dementia 2017–2025. Geneva: World Health Organization, https://iris.who.int/handle/10665/259615 (2017, accessed 2 February 2024).
2.
RizziLRossetIRoriz-CruzM. Global epidemiology of dementia: Alzheimer’s and vascular types. BioMed Res Int2014; 2014: 1–8.
3.
PrinceMWimoAGuerchetM, et al.World Alzheimer Report 2015. The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends. London, UK: Alzheimer’s Disease International, 2015.
4.
NicholsESteinmetzJDVollsetSE, et al.Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019. Lancet Public Health2022; 7: 105–125.
5.
DeTureMADicksonDW. The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener2019; 14: 32.
6.
BloomGS. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol2014; 71: 505.
7.
TeunissenCEVerberkIMWThijssenEH, et al.Blood-based biomarkers for Alzheimer’s disease: towards clinical implementation. Lancet Neurol2022; 21: 66–77.
8.
WalhovdKBFjellAMBrewerJ, et al.Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. Am J Neuroradiol2010; 31: 347–354.
9.
PalmqvistSZetterbergHMattssonN, et al.Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology2015; 85: 1240–1249.
10.
HameedSFuhJ-LSenanarongV, et al.Role of fluid biomarkers and PET imaging in early diagnosis and its clinical implication in the management of Alzheimer’s disease. J Alzheimers Dis Rep2020; 4: 21–37.
11.
ShenXLiJWangH, et al.Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer’s disease pathology and clinical progression in older adults without dementia. Alzheimers Dement (Amst)2020; 12: e12104.
12.
MattssonNAndreassonUZetterbergH, et al.Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol2017; 74: 557.
13.
JackCRBennettDABlennowK, et al.A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology2016; 87: 539–547.
14.
YuJLiJSucklingJ, et al.Frequency and longitudinal clinical outcomes of Alzheimer’s AT(N) biomarker profiles: a longitudinal study. Alzheimers Dement2019; 15: 1208–1217.
15.
ParkJ-CHanS-HYiD, et al.Plasma tau/amyloid-β1–42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer’s disease. Brain2019; 142: 771–786.
16.
AgarwalMKhanS. Plasma lipids as biomarkers for Alzheimer’s disease: a systematic review. Cureus2020; 10: 12.
17.
AdewaleBACokerMMOgunniyiA, et al.Biomarkers and risk assessment of Alzheimer’s disease in low- and middle-income countries. J Alzheimers Dis2023; 95: 1339–1349.
18.
ChiuM-JChenT-FHuC-J, et al.Nanoparticle-based immunomagnetic assay of plasma biomarkers for differentiating dementia and prodromal states of Alzheimer’s disease – A cross-validation study. Nanomedicine Nanotechnol Biol Med2020; 28: 102182.
19.
VerberkIMWMisdorpEOKoelewijnJ, et al.Characterization of pre-analytical sample handling effects on a panel of Alzheimer’s disease-related blood-based biomarkers: results from the standardization of Alzheimer’s blood biomarkers (SABB) working group. Alzheimers Dement2022; 18: 1484–1497.
20.
AkinyemiROOwolabiMOOkubadejoN, et al.The African dementia consortium. Lancet Neurol2023; 22: 28–29.
21.
WilsonDHRissinDMKanCW, et al.The Simoa HD-1 analyzer: a novel fully automated digital immunoassay analyzer with single-molecule sensitivity and multiplexing. SLAS Technol2016; 21: 533–547.
22.
JiangXBahorikALGraff-RadfordNR, et al.Association of plasma amyloid-β and dementia among Black and white older adults. J Alzheimers Dis2024; 99: 787–797.
23.
WindonCIaccarinoLMundadaN, et al.Comparison of plasma and CSF biomarkers across ethnoracial groups in the ADNI. Alzheimers Dement (Amst)2022; 14: e12315.
24.
DenizKHoCCGMalphrusKG, et al.Plasma biomarkers of Alzheimer’s disease in African Americans. J Alzheimers Dis2021; 79: 323–334.
25.
Molina-HenryDPRamanRLiuA, et al.Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer’s disease trial. Alzheimers Dement2024; 20: 3827–3838.
26.
GriswoldAJRajabliFGuT, et al.Generalizability of tau and amyloid plasma biomarkers in Alzheimer's disease cohorts of diverse genetic ancestries. Alzheimers Dement2025; 21: e14367.
27.
GriswoldAJRajabliFGuT, et al.Tau and amyloid plasma biomarker analysis in Alzheimer’s disease cohorts from diverse genetic ancestries. Alzheimers Dement2023; 19: e078942.
28.
IkangaJPatelSSRobertsBR, et al.Association of plasma biomarkers with cognitive function in persons with dementia and cognitively healthy in the Democratic Republic of Congo. Alzheimers Dement (Amst)2023; 15: e12496.
29.
GiacomucciGMazzeoSBagnoliS, et al.Plasma neurofilament light chain as a biomarker of Alzheimer’s disease in subjective cognitive decline and mild cognitive impairment. J Neurol2022; 269: 4270–4280.
30.
OecklPHalbgebauerSAnderl-StraubS, et al.Glial fibrillary acidic protein in serum is increased in Alzheimer’s disease and correlates with cognitive impairment. J Alzheimer’s Dis2019; 67: 481–488.
31.
ChatterjeePPedriniSDoeckeJD, et al.Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer’s disease continuum: a cross-sectional and longitudinal study in the AIBL cohort. Alzheimers Dement2023; 19: 1117–1134.
32.
LewczukPErmannNAndreassonU, et al.Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease. Alzheimers Res Ther2018; 10: 71.
33.
AltmannPLeutmezerFZachH, et al.Serum neurofilament light chain withstands delayed freezing and repeated thawing. Sci Rep2020; 10: 19982.
